January 15, 2024
GlaxoSmithKline said on January 15 that its respiratory syncytial virus (RSV) vaccine Arexvy is now available in Japan for the prevention of RSV infections in people aged 60 and older. Arexvy was approved as Japan’s first RSV jab in September...read more